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Background
Cyclic nucleotide phosphodiesterases (PDEs) play a key
role in signal transduction downstream RCPGs by hydro-
lyzing specifically cyclic nucleotides. PDE is a superfamily
of enzymes presently constituted of 11 gene families [1].
Among them, the PDE5 family is constituted by an unique
gene with three different splice variants [2], and is charac-
terized by its specificity for cGMP hydrolysis, the presence
of cGMP-binding sites and its insensitivity to calcium-
camoldulin. We have characterized PDE5 in vascular
smooth muscle from human, bovine and rat aorta, and
showed that zaprinast specifically inhibits PDE5 [3]. The
specific inhibition of vascular PDE5 by zaprinast (1 μM)
induces relaxation of rat aorta along with an increase in
cGMP level [4]. Furthermore, we showed that PDE5 in
platelets participates in controling aggregation [5]. The
aim of the present study was to compare peptidic
sequences, biochemical properties and pharmacological
sensitivities of vascular PDE5 and platelet PDE5.
Materials and methods
Cytosolic fractions of smooth muscle from bovine aorta
and from human platelet were submitted to DEAE-sepha-
rose chromatography and subsequently to affinity chro-
matography on ECH-Sepharose 4B resin coupled with
NH2-zaprinast. Fractions containing PDE5 were submit-
ted to Western blot and to gel electrophoresis. PDE5
bands were excised from gel and submitted to gel-diges-
tion in order to perform MALDI-TOF analysis. PDE activ-
ity was determined by a radioenzymatic assay using 3H-
cGMP as a tracer [5]; Km and Vmax determinations as well
as Ki were determined on purified PDE5s. N-alkylated
zaprinast was synthetized by L Lebeau using as a scaffold
NH2-zaprinast.
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Coomassie blue coloration of electrophoresed purified
vascular smooth muscle PDE5 and platelet PDE5 (Figure
1A) shows two signals for platelet (a major band at 85-
kDa and a minor band at 90-kDa; lane 1) and one signal
for vascular smooth muscle (90-kDa band; lane 2).
Immunodetection using a polyclonal specific antibody
against bovine lung PDE5 [6] (Figure 1B) shows that
platelet PDE5 is a 85-kDa protein (lane 1), whereas vascu-
lar smooth muscle PDE5 is a 90-kDa protein (lane 2).
MALDI-TOF analysis obtained for trypsic peptides from
the 90-kDa Coomassie band of vascular PDE5 (Figure 1A,
lane 2) allowed to identify, after Mascot Search, this vas-
cular protein as belonging to PDE5 family when com-
pared with bovine lung PDE5, with a significant score of
126 (significant score being > 60). A similar analysis per-
formed on the 85-kDa band from platelet showed a 32%
overlap when compared with the bovine lung PDE5
sequence. Furthermore, a score of 148 was obtained for
matching platelet PDE5 sequence with human PDE5A2
sequence. Altogether, these data show that vascular
smooth muscle PDE5 and human platelet PDE5 are dif-
ferent proteins.
Table 1 shows that platelet PDE5 differs significantly from
vascular PDE5 by their submicromolar Km values, platelet
PDE5 displaying a slightly higher affinity for cGMP. Zap-
rinast, the conventional inhibitor of PDE5, is 2-fold more
active in inhibiting vascular PDE5 than platelet PDE5.
NH2-zaprinast is 6-fold more potent than zaprinast on
both vascular PDE5 and platelet PDE5. N-alkylated-zapri-
nast preferentially inhibits vascular PDE5 with a Ki value
of 32 pM, thus being 1,800-fold more potent than NH2-
zaprinast, and it is 56-fold more potent in inhibiting vas-
cular PDE5 than platelet PDE5. It should be noticed that
no such a difference in potencies was observed between
eucilat and alkyl-eucilat, both of them inhibiting vascular
PDE5 and platelet PDE5 in the micromolar range. Furthe-
more, sildenafil cannot discriminate vascular PDE5 from
platelet PDE5.
Conclusion
Our results show that vascular PDE5 and platelet PDE5
are different proteins which can be discriminate by N-
alkylated-zaprinast and suggest that they might represent
different PDE5 variants which can be selectively inhibited.
These data open new therapeutic opportunities for using
PDE5 inhibitor treatment in patients treated with antiag-
gregant.
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Table 1: Biochemical and pharmacological comparisons of vascular and platelet PDE5s
Vascular PDE5 Platelet PDE5
Km (μM) 0.44 ± 0.02 0.31 ± 0.04
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